SON Stock Recent News

HARTSVILLE, S.C., May 08, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (NYSE: SON), a global leader in value-added sustainable packaging, today released its 2024 Corporate Sustainability Report, marking its transformation into a more sustainable packaging company following the acquisition of Eviosys, Europe's leading metal packaging manufacturer.

The Securities Act of 1934 established many of the US rules for the securities market in the aftermath of the 1929 Stock Market Crash that ushered in The Great Depression.

Sonoco (SON) came out with quarterly earnings of $1.38 per share, missing the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.12 per share a year ago.

HARTSVILLE, S.C., April 29, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a core mid-cap growth and value equity which is a global leader in high-value sustainable packaging, today reported financial results for the first quarter ended March 30, 2025.

HARTSVLLE, S.C., April 28, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a global leader in high-value sustainable packaging, will announce first quarter 2025 results on Tuesday, April 29, 2025 after the market closes. The Company will host a conference call to discuss these results on Wednesday, April 30, 2025, at 8:30 a.m. Eastern Time.

HARTSVILLE, S.C., April 22, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (NYSE: SON), a global leader in high-value sustainable packaging, has been named to USA TODAY's list of America's Climate Leaders 2025.

Sonoco (SON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HARTSVILLE, S.C., April 16, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Sonoco (NYSE: SON) today increased its quarterly common stock dividend to $0.53 per shares as it celebrated the 100th consecutive year of paying dividends to its shareholders at the Company's annual meeting.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )